AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14980755 — intervention group
Group type: COMPARATOR
Intervention: Other medical therapies (oral contraceptives and/or prostaglandin synthetase inhibitor)
Number of subjects: 63
Study 11777881 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (2-4 g intravenously)
Number of subjects: 105
Study 11777881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously)
Number of subjects: 105
Study 9690948 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler (large volume spacer)
Number of subjects: 10
Study 9690948 — intervention group
Group type: COMPARATOR
Intervention: Volumatic (large volume spacer)
Number of subjects: 10
Study 9690948 — intervention group
Group type: COMPARATOR
Intervention: Aerochamber (small volume spacer)
Number of subjects: 10
Study 9690948 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI alone
Number of subjects: 10
Study 9690948 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler vs Volumatic
Number of subjects: 10
Study 9690948 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler vs Aerochamber
Number of subjects: 10
Study 8121740 — intervention group
Group type: EXPERIMENTAL
Intervention: Salted peas or green beans (10 occasions over 10 days)
Number of subjects: 36
Study 8121740 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsalted peas or green beans (10 occasions over 10 days)
Number of subjects: 36
Study 8121740 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk feeding
Number of subjects: 36
Study 8121740 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 36
Study 8121740 — intervention group
Group type: COMPARATOR
Intervention: Control food (not specified)
Number of subjects: 36
Study 8121740 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult ratings of infants' responses
Number of subjects: 36
Study 2764537 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 0
Study 2764537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 0
Study 2764537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 0
Study 939070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 23
Study 939070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol with diuretic
Number of subjects: 23
Study 31773765 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic resection of the prostate (PKRP)
Number of subjects: 101
Study 31773765 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma button transurethral vapour enucleation of the prostate (PVEP)
Number of subjects: 101
Study 31773765 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PVEP and PKRP
Number of subjects: 101
Study 30910592 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib combined with chloroquine
Number of subjects: 0
Study 30910592 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 0
Study 30910592 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of autophagy
Number of subjects: 0
Study 30910592 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of Beclin-1
Number of subjects: 0
Study 30350258 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-home physical activity measured by accelerometer and physical activity diary.
Number of subjects: 334
Study 30350258 — intervention group
Group type: COMPARATOR
Intervention: Social isolation measured using the Lubben Social Network Scale (LSNS-6).
Number of subjects: 334
Study 27200503 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.01, 0.1 and 0.3 mg per kg body weight) administered once in a 1-day-long trial
Number of subjects: 33
Study 27200503 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.08 and/or 0.12 mg kg(‐1)) administered for 16 weeks
Number of subjects: 33
Study 27200503 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 16 weeks
Number of subjects: 33
Study 24369178 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Self-Efficacy (PSE) instrument for dietary and physical activity behaviors
Number of subjects: 162
Study 23146150 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide (1 mg/d)
Number of subjects: 40
Study 23146150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20430601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg once daily
Number of subjects: 480
Study 20430601 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg twice daily
Number of subjects: 480
Study 18043104 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 58
Study 18043104 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 58
Study 16086757 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with surfactant pretreatment (3-h application at 250 microA cm(‐2))
Number of subjects: 24
Study 16086757 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis alone
Number of subjects: 24
Study 16086757 — intervention group
Group type: COMPARATOR
Intervention: Control (passive treatments)
Number of subjects: 24
Study 11850863 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccine
Number of subjects: 101
Study 11850863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 10597806 — intervention group
Group type: EXPERIMENTAL
Intervention: Medially linked KAFOs
Number of subjects: 9
Study 10597806 — intervention group
Group type: COMPARATOR
Intervention: Unlinked KAFOs
Number of subjects: 9
Study 7487465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir during ALA therapy (group 1)
Number of subjects: 40
Study 7487465 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis for CMV disease (group 2)
Number of subjects: 40
Study 1766705 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin-sulfisoxazole
Number of subjects: 0
Study 1766705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 0
Study 1766705 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0
Study 1766705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6127719 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide (160 micrograms daily)
Number of subjects: 12
Study 6127719 — intervention group
Group type: COMPARATOR
Intervention: thiazinamium methyl sulphate (900 mg daily)
Number of subjects: 12
Study 6127719 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 12
Study 6127719 — intervention group
Group type: COMPARATOR
Intervention: thiazinamium methyl sulphate
Number of subjects: 12
Study 30797041 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and lifestyle intervention
Number of subjects: 0
Study 30797041 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 27814302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication (dosage titrated by physician)
Number of subjects: 53
Study 27814302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 25896973 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular analysis for actionable genomic data
Number of subjects: 93
Study 25896973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor biopsy and archived tumor samples collection
Number of subjects: 93
Study 25896973 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for molecular targets
Number of subjects: 93
Study 25896973 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status assessment
Number of subjects: 93
Study 25010541 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid composite with antibacterial system
Number of subjects: 9
Study 25010541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid composite
Number of subjects: 9
Study 25010541 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 9
Study 25010541 — intervention group
Group type: COMPARATOR
Intervention: Control (non-restored dentine samples)
Number of subjects: 9
Study 22100906 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus weight-adjusted dalteparin (WAD) for 12 weeks
Number of subjects: 123
Study 22100906 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 123
Study 20558428 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost 0.03%
Number of subjects: 25
Study 20558428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% + Dorzolamide 2%
Number of subjects: 25
Study 17335691 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid growth factors (MGFs) used at varied schedules, doses, and durations differing from FDA approved prescribing information.
Number of subjects: 0
Study 17335691 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid growth factors (MGFs) administered on the same day as chemotherapy.
Number of subjects: 0
Study 16291353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hood (1.5 mg epinephrine in 4 mL saline [3%])
Number of subjects: 49
Study 16291353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask (1.5 mg epinephrine in 4 mL saline [3%])
Number of subjects: 49
Study 16291353 — intervention group
Group type: COMPARATOR
Intervention: Hood
Number of subjects: 49
Study 16291353 — intervention group
Group type: COMPARATOR
Intervention: Mask
Number of subjects: 49
Study 16291353 — intervention group
Group type: COMPARATOR
Intervention: Indifferent
Number of subjects: 49
Study 12406071 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-blood point-of-care testing (POCT) monitor (CoaguChek)
Number of subjects: 46
Study 12406071 — intervention group
Group type: COMPARATOR
Intervention: Hospital laboratory coagulometer prothrombin time (PT) testing
Number of subjects: 46
Study 12406071 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction with community POCT monitoring
Number of subjects: 46
Study 10460118 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions (walking, standing balance, upper limb movement pattern)
Number of subjects: 89
Study 10460118 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy interventions (physical function, social and leisure activities, other)
Number of subjects: 89
Study 10460118 — intervention group
Group type: EXPERIMENTAL
Intervention: Median treatment time for a session
Number of subjects: 89
Study 10460118 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in treatment delivery
Number of subjects: 89
Study 7528271 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE chemotherapy with G‐CSF
Number of subjects: 25
Study 7528271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 (n = 6) treated every 3 weeks
Number of subjects: 25
Study 7528271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2 (n = 7) treated every 2 weeks
Number of subjects: 25
Study 7528271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 3 (n = 12) treated every 2 weeks
Number of subjects: 25
Study 2381617 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin cream
Number of subjects: 67
Study 2381617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concentrations of clindamycin cream (0.1% and 1%)
Number of subjects: 67
Study 2381617 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 67
Study 7053123 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ventilation
Number of subjects: 35
Study 7053123 — intervention group
Group type: COMPARATOR
Intervention: Early extubation
Number of subjects: 35
Study 30667337 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic antenna placement
Number of subjects: 31
Study 30667337 — intervention group
Group type: COMPARATOR
Intervention: Freehand antenna placement
Number of subjects: 31
Study 28778854 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced personal health record only
Number of subjects: 209
Study 28778854 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator only
Number of subjects: 209
Study 28778854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enhanced personal health record and patient navigator
Number of subjects: 209
Study 28778854 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 209
Study 26381275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (150 mg oral dose of crizotinib)
Number of subjects: 0
Study 26381275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (250 mg oral dose of crizotinib)
Number of subjects: 0
Study 23224127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) early treatment (IVB1)
Number of subjects: 65
Study 23224127 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) early treatment (IVT1)
Number of subjects: 65
Study 23224127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) late treatment (IVB2)
Number of subjects: 65
Study 23224127 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) late treatment (IVT2)
Number of subjects: 65
Study 18165205 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 117
Study 18165205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (other drug than spironolactone)
Number of subjects: 117
Study 15493232 — intervention group
Group type: EXPERIMENTAL
Intervention: Code-based classroom instruction with a supplemental maintenance intervention
Number of subjects: 59
Study 15493232 — intervention group
Group type: COMPARATOR
Intervention: Only code-based classroom instruction
Number of subjects: 59
Study 10718784 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g in 200 ml water)
Number of subjects: 9
Study 10718784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 9
Study 10718784 — intervention group
Group type: COMPARATOR
Intervention: Water (200 ml) (control)
Number of subjects: 9
Study 9177508 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) alone
Number of subjects: 50
Study 9177508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of endoscopic variceal ligation (EVL) and endoscopic sclerotherapy (EST)
Number of subjects: 50
Study 8415265 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide forte aerosol Polfa, 200 micrograms four times daily
Number of subjects: 30
Study 8415265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8415265 — intervention group
Group type: COMPARATOR
Intervention: Foreign made analogue
Number of subjects: 30
Study 3537898 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered ginger root (Zingiber officinale)
Number of subjects: 8
Study 3537898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31739249 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection Engagement and Savoring Positivity (DESP) task
Number of subjects: 92
Study 31739249 — intervention group
Group type: COMPARATOR
Intervention: Control condition (placebo)
Number of subjects: 92
Study 31739249 — intervention group
Group type: COMPARATOR
Intervention: Control condition (excluding savoring)
Number of subjects: 92
Study 30592302 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 848
Study 30592302 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 848
Study 28700282 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyfour®-TT
Number of subjects: 244
Study 28700282 — intervention group
Group type: COMPARATOR
Intervention: Quadrovax®
Number of subjects: 244
Study 26546142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine added to standard-of-care (SoC)
Number of subjects: 10000
Study 26546142 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) alone
Number of subjects: 10000
Study 23609167 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC patients with cirrhosis
Number of subjects: 150
Study 23609167 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC patients with chronic hepatitis B
Number of subjects: 150
Study 23609167 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC patients with chronic hepatitis C
Number of subjects: 150
Study 23609167 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC patients with alcohol use
Number of subjects: 150
Study 23609167 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC patients with smoking
Number of subjects: 150
Study 23609167 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC patients with diabetes (subgroup with no traditional risk factors)
Number of subjects: 150
Study 21087288 — intervention group
Group type: EXPERIMENTAL
Intervention: NETE-8 (norethisterone enanthate 200 mg every 8 weeks plus testosterone undecanoate 1000 mg)
Number of subjects: 50
Study 21087288 — intervention group
Group type: EXPERIMENTAL
Intervention: NETE-6/12 (norethisterone enanthate 200 mg every 6 weeks for 12 weeks and then every 12 weeks plus testosterone undecanoate 1000 mg)
Number of subjects: 50
Study 21087288 — intervention group
Group type: EXPERIMENTAL
Intervention: NETE-6/12/0 (norethisterone enanthate 200 mg every 6 weeks for 12 weeks and then testosterone undecanoate plus placebo every 12 weeks)
Number of subjects: 50
Study 21087288 — intervention group
Group type: COMPARATOR
Intervention: NETE-0/0 (placebo)
Number of subjects: 50
Study 19654570 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d.
Number of subjects: 30
Study 19654570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16995976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined non-biological artificial liver treatment
Number of subjects: 103
Study 16995976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no combined non-biological artificial liver treatment)
Number of subjects: 103
Study 15591335 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR assay of 21 genes
Number of subjects: 668
Study 15591335 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence score from RT-PCR assay
Number of subjects: 668
Study 11389408 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise group
Number of subjects: 39
Study 11389408 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 9024169 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg) after rifampin (600 mg once daily for 5 days)
Number of subjects: 10
Study 8101045 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil administered intravenously in small, incremental doses
Number of subjects: 0
Study 8101045 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 2874278 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin
Number of subjects: 21
Study 2874278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30545338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 148
Study 30545338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 26494727 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 0
Study 26494727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26494727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower mean corpuscular volumes
Number of subjects: 0
Study 26494727 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher birth weights
Number of subjects: 0
Study 24956863 — intervention group
Group type: EXPERIMENTAL
Intervention: Xihuangwan (XHW)
Number of subjects: 84
Study 24956863 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical treatment + chemotherapy regimen PTX + EPI + CTX)
Number of subjects: 84
Study 21131072 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with initial thrombus aspiration (IT)
Number of subjects: 100
Study 21131072 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with tirofiban infusion (TI)
Number of subjects: 100
Study 21131072 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with both treatments (IT+TI)
Number of subjects: 100
Study 21131072 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 100
Study 21131072 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (IT)
Number of subjects: 100
Study 21131072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban infusion (TI)
Number of subjects: 100
Study 21131072 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration with tirofiban (IT+TI)
Number of subjects: 100
Study 21131072 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 20518784 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 122
Study 20518784 — intervention group
Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 122
Study 20518784 — intervention group
Group type: EXPERIMENTAL
Intervention: Aktilite CL128
Number of subjects: 122
Study 18693409 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenotherapy
Number of subjects: 237
Study 18693409 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 237
Study 16324409 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (GH) 1440 mg/day for 4 weeks
Number of subjects: 142
Study 16324409 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulfate (GS) 1500 mg/day for 4 weeks
Number of subjects: 142
Study 12934980 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day increased to 60 mg/day)
Number of subjects: 24
Study 12934980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12934980 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (continued treatment)
Number of subjects: 24
Study 10848459 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat Health (civil remedy program)
Number of subjects: 100
Study 10848459 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (patrol response)
Number of subjects: 100
Study 8848916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (0.4 mg) and intramuscular (4 mg) morphine (IT‐IM‐group)
Number of subjects: 20
Study 8848916 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal (0.4 mg) morphine and intramuscular saline (IT‐group)
Number of subjects: 20